Skip to main content
Premium Trial:

Request an Annual Quote

Second Genome: Joseph Dal Porto

Joseph Dal Porto has been appointed as CSO of Second Genome. Previously, he was VP at Pfizer's emerging science & innovation division and site head of Pfizer's Centers for Therapeutic Innovation. Prior to that, he was a cofounder and director of preclinical research and development at Modus BioMedicine, a spinout from Roche. Dal Porto holds a PhD in microbiology and immunology from the University of Maryland School of Medicine and a BS in biochemistry from Johns Hopkins University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.